← Evidence map

ArticleDiabetes & metabolic syndrome

Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.).

Awadhesh Kumar Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.). | OpenQuestion